US Presidential Debates Begin: Pharma Is Favorite Villain – But Issues Focus Elsewhere
Executive Summary
To no one’s surprise, attacks on the drug industry are a recurring and unifying theme for the Democratic Presidential candidates as they enter the debate cycle. But rhetoric aside, the health policy proposals getting the most airtime are more threatening for other sectors.
You may also be interested in...
Trump’s Maximum Pressure Campaign On US Drug Pricing
President Trump isn’t going to let the Democrats own the drug pricing debate heading into the 2020 elections, so biopharma companies can look forward to many more headlines like the importation announcement on 31 July. When will it end?
White House Exec Order Will Bring US Parity With Lowest Drug Prices Abroad, Trump Says
Remarks to reporters prompt surprise and confusion among stakeholders and likely reflect the president’s impatience with the pace of regulatory and legislative pricing reforms.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.